Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mediwound Ltd MDWD

Healthcare
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in... see more

Recent & Breaking News (NDAQ:MDWD)

MediWound to Report Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

MediWound Announces Formation of Strategic Advisory Board

GlobeNewswire October 25, 2022

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

GlobeNewswire October 18, 2022

MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings

GlobeNewswire October 7, 2022

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million

GlobeNewswire September 22, 2022

EMA Accepts MediWound's Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

GlobeNewswire September 20, 2022

MediWound's NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

GlobeNewswire September 12, 2022

IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum "Homi" Shamir to its Board of Directors

GlobeNewswire August 23, 2022

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

GlobeNewswire August 9, 2022

MediWound Enhances Its Board and Executive Leadership Team

GlobeNewswire August 8, 2022

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

GlobeNewswire August 3, 2022

MediWound Schedules Second Quarter 2022 Financial Results

GlobeNewswire August 1, 2022

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

GlobeNewswire July 11, 2022

MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

GlobeNewswire July 8, 2022

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

GlobeNewswire July 7, 2022

MediWound to Host a Key Opinion Leader Investor Day on EscharEx

GlobeNewswire July 5, 2022

MediWound Names Mr. Tzvi Palash as Chief Operating Officer

GlobeNewswire June 30, 2022

MediWound Announces CEO Transition

GlobeNewswire May 17, 2022

MediWound Reports First Quarter 2022 Financial Results

GlobeNewswire May 17, 2022

MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

GlobeNewswire May 12, 2022